Finally, a Vaccine for Cancer

Original Media · 24m · English · Podcast · The Daily

TLDR

A personalized mRNA vaccine for melanoma, developed by Merck and Moderna, reduced cancer recurrence by 42% at two years in a trial of over 1,100 patients. The vaccine sequences each patient's tumor, identifies up to 34 unique mutations, and delivers mRNA instructions for the body to produce those neoantigens, training the immune system to attack residual cancer cells when combined with a checkpoint inhibitor. This marks the first major success after more than a century of failed attempts at therapeutic cancer vaccines. Researchers are now testing the approach in pancreatic and other cancers, and exploring off-the-shelf preventive vaccines for high-risk genetic populations. The breakthrough was enabled by cheap genome sequencing, checkpoint inhibitor drugs, and mRNA manufacturing advances from COVID vaccines. Personalized vaccines remain expensive but are comparable to existing cancer therapies costing hundreds of thousands of dollars. The field's long-term goal is shifting from treating recurrence to preventing cancer entirely in high-risk individuals. FDA approval is being pursued based on the two-year data, though longer follow-up is needed.

For you

PRO members can sign in and request more information — or their own version of this digest, tuned to what they care about.

Sign in to unlock

Surprising Insights

•

The vaccine is given *after* cancer diagnosis and surgery, not before — it treats established disease by preventing recurrence, flipping the traditional preventive vaccine paradigm.

•

Cancer cells actively hijack the immune system's 'brakes' (checkpoint pathways) to shut down attack; the vaccine provides the target, but the checkpoint inhibitor must release the brakes for the immune response to actually kill tumor cells.

•

The COVID pandemic, despite its devastation, accelerated mRNA manufacturing technology by years, directly enabling this cancer breakthrough — a rare case where a global crisis sped up an unrelated medical advance.

•

William Coley's 1890s bacterial injections ('Coley's toxins') were dismissed as quackery, but the underlying principle — stimulating innate immunity to attack tumors — was fundamentally correct and is now the basis of modern immuno-oncology.

•

The vaccine does not target the cancer cells directly; it instructs the patient's own cells to produce 'enemy flag' proteins so the immune system learns to recognize and hunt cells displaying those flags — a delegation strategy rather than a direct attack.

Key takeaways

•

The melanoma vaccine is the first therapeutic cancer vaccine to show efficacy in a randomized Phase 3 trial, achieving a 42% reduction in recurrence at two years compared to standard treatment alone.

•

Each vaccine is manufactured individually: after surgical tumor removal, the tumor's DNA is sequenced to identify mutations, algorithms predict up to 34 neoantigens most visible to the immune system, and mRNA encoding those neoantigens is produced — a process taking weeks per patient.

•

The vaccine only works in combination with a checkpoint inhibitor (pembrolizumab/Keytruda), which releases the immune system's natural brakes that cancer cells hijack to evade detection; neither the vaccine nor the checkpoint inhibitor alone produced this level of benefit in prior studies.

•

Melanoma's high mutation burden makes it unusually visible to the immune system, which is why it succeeded first; 'cold' tumors like pancreatic, breast, and colon cancers have fewer mutations and may not respond as well, though a small pancreatic cancer trial showed early promise.

•

The mRNA platform's speed and customizability — matured during COVID vaccine development — is what made individualized cancer vaccines practically manufacturable; before COVID, producing a unique mRNA vaccine per patient in weeks was not feasible at scale.

•

Researchers are pursuing two parallel paths: continuing personalized therapeutic vaccines for treated patients, and developing 'off-the-shelf' preventive vaccines targeting shared antigens for people with inherited high cancer risk (e.g., BRCA mutations, Lynch syndrome), which could reach more people at lower cost.

•

The 42% figure is a relative risk reduction in recurrence-free survival at two years; overall survival data requires longer follow-up, and the absolute benefit depends on each patient's baseline recurrence risk after surgery.

•

The concept of therapeutic cancer vaccines dates to the 1890s when surgeon William Coley observed tumor regression after bacterial infections, but lacked the tools — genomic sequencing, checkpoint inhibitors, mRNA platforms — to harness the principle safely and precisely until now.

Notable quotes

“So, scientists have tried and failed for decades, if not longer, to develop a vaccine that could be used to treat cancer. But it's really a very challenging thing.”

▸ Notable quotes · 1:48

“And cancer is, even within a specific cancer, it's very varied. It's very heterogeneous. One person's cancer is not exactly the same as the next person's cancer.”

▸ Notable quotes · 2:12

“The way we traditionally think about vaccines against infectious disease being given when somebody is healthy and has no exposure. And this is a different paradigm where you're using it to treat cancer once somebody has already been diagnosed with it.”

▸ Notable quotes · 3:19

“They're trying to predict which of those mutations, because in melanoma, a cancer cell can have hundreds of mutations. They're trying to predict which one of those our immune system can see and recognize and then attack.”

▸ Notable quotes · 4:36

“These mutations produce proteins on the cell surface, which kind of are like enemy flags to our immune system.”

▸ Notable quotes · 4:46

“The experts I talked to say that's on par with some of their biggest breakthroughs.”

▸ Notable quotes · 7:56

Chapters

•

0:00 — DealBook Summit Promo: Andrew Ross Sorkin promotes the upcoming DealBook Summit on November 18th featuring leaders like J.D. Vance, Elon Musk, and Christine Lagarde.

•

0:30 — Melanoma Vaccine Breakthrough Announced: Michael Barbaro introduces the episode; Nina Agrawal reports the first successful therapeutic cancer vaccine — a personalized mRNA vaccine for melanoma showing 42% recurrence reduction at two years.

•

3:30 — How the Personalized Vaccine Works: Detailed explanation: tumor sequencing after surgery identifies mutations; algorithms select up to 34 neoantigens; mRNA encoding them is injected; immune system produces 'enemy flag' proteins and learns to attack cells displaying them.

•

7:00 — Trial Results and Significance: Over 1,100 stage 2-4 melanoma patients received nine vaccine doses plus checkpoint inhibitor; 42% less recurrence at two years, also reduced distant metastasis; experts call it on par with major oncology breakthroughs; FDA application planned.

•

9:48 — Century of Failure: Cancer Vaccine History: Traces 130-year history from William Coley's 1890s bacterial injections (dismissed as quackery) through immunotherapy rise in 1980s, checkpoint inhibitors in 1990s-2000s, to convergence of genomics, checkpoint blockade, and mRNA tech.

•

12:12 — Enabling Technologies Converge: Three key advances made this possible: cheap/rapid genome sequencing to identify neoantigens, checkpoint inhibitors to release immune brakes, and COVID-accelerated mRNA manufacturing for rapid individualized production.

•

15:42 — Future: Other Cancers and Prevention: Melanoma may be uniquely responsive due to high mutations; pancreatic cancer trial shows early promise; researchers pursue off-the-shelf preventive vaccines for high-risk genetic populations (BRCA, Lynch syndrome) as the ultimate goal.

•

17:00 — Cost, Access, and Closing: Personalized vaccines cost hundreds of thousands like other cancer therapies; prevention vaccines could be cheaper and broader; episode ends with news briefs on FAA ground stop and Senate leadership race.

Speakers

•

Michael Barbaro — Host

•

Nina Agrawal — Health Reporter

•

Andrew Ross Sorkin — DealBook Founder/Columnist

•

Dana — NYT Subscriber

•

Sarah Koenig — Podcast Host

•

Sean Duffy — Transportation Secretary

•

Chris Van Hollen — U.S. Senator

⋮